A child with CARD14-associated papulosquamous eruption (CAPE) successfully treated with ustekinumab

Pediatr Dermatol. 2023 Nov-Dec;40(6):1104-1106. doi: 10.1111/pde.15336. Epub 2023 May 23.

Abstract

CARD14-associated papulosquamous eruption (CAPE) is a rare inflammatory skin eruption that can have features of psoriasis, pityriasis rubra pilaris, and erythroderma. This skin condition is known for its resistance to topical or conventional systemic therapies. Successful treatment of CAPE with anti-IL-12/IL-23 and IL-17 inhibitors has been reported. We present a case of a 2-year-old girl with CAPE who was successfully treated with ustekinumab.

Keywords: erythroderma; pediatric; ustekinumab.

Publication types

  • Case Reports

MeSH terms

  • CARD Signaling Adaptor Proteins
  • Child
  • Child, Preschool
  • Dermatitis, Exfoliative*
  • Dermatologic Agents* / therapeutic use
  • Female
  • Guanylate Cyclase
  • Humans
  • Membrane Proteins
  • Pityriasis Rubra Pilaris* / drug therapy
  • Psoriasis* / drug therapy
  • Ustekinumab / therapeutic use

Substances

  • Ustekinumab
  • Dermatologic Agents
  • CARD14 protein, human
  • Guanylate Cyclase
  • Membrane Proteins
  • CARD Signaling Adaptor Proteins